News & Updates

Show Multimedia Only
Fluvoxamine wins, metformin disappoints in long COVID fatigue
Fluvoxamine wins, metformin disappoints in long COVID fatigue
19 Jun 2026 byElvira Manzano

The antidepressant fluvoxamine reduces long COVID fatigue, whereas the antidiabetic agent metformin fails to outperform placebo in the randomized REVIVE-TOGETHER trial.

Fluvoxamine wins, metformin disappoints in long COVID fatigue
19 Jun 2026
Reduced RT plus chemo-immunotherapy feasible in older/frail NSCLC patients
Reduced RT plus chemo-immunotherapy feasible in older/frail NSCLC patients
18 Jun 2026 byStephen Padilla

In older or frail patients with stage III non-small cell lung cancer (NSCLC), undergoing reduced radiotherapy (RT) followed by sequential chemo-immunotherapy results in survival outcomes similar to standard RT, indicating its utility in vulnerable populations, suggests a study.

Reduced RT plus chemo-immunotherapy feasible in older/frail NSCLC patients
18 Jun 2026
Topicals are first in the new treatment order for knee osteoarthritis
Topicals are first in the new treatment order for knee osteoarthritis
18 Jun 2026 byAssoc Prof Sanjiv Rampal, Orthopaedic Consultant, IMU School of Medicine

Knee osteoarthritis, increasingly common with ageing and obesity, often first presents to GPs, whose initial treatment decisions strongly shape outcomes and costs.

Topicals are first in the new treatment order for knee osteoarthritis
18 Jun 2026